Etest Cefotaxime CT 256 WW and Etest Cefotaxime CT 256 US. in vitro diagnostic.

FDA Device Recall #Z-1947-2015 — Class II — June 12, 2015

Recall Summary

Recall Number Z-1947-2015
Classification Class II — Moderate risk
Date Initiated June 12, 2015
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm BioMerieux SA
Location Marcy L'Etoile
Product Type Devices
Quantity 674

Product Description

Etest Cefotaxime CT 256 WW and Etest Cefotaxime CT 256 US. in vitro diagnostic.

Reason for Recall

QC results were out of range resulting in false resistant strains.

Distribution Pattern

Worldwide Distribution - USA (nationwide) to the states of AL, AR, CA, CO, FL, GA, IL, IN, KY, MD, MI, MN, MO, NE, NY, NC, OH, OK, OR, PA, TN, TX, UT, VA, WA, WV and WI., and to the countries of: Austria, Australia, Canada, Switzerland, Germany, Spain, France, United Kingdom, Greece, Hong Kong, India, Italy, Japan, Netherlands, Poland, Sweden, Thailand, Turkey, Saudi Arabia, Philippines, Slovenia, Kuwait, Brazil, Chile, Czech Republic, Algeria, South Africa, Kosovo, Costa Rica, Belarus, Guam, Honduras and Vietnam.

Lot / Code Information

1002774320, 1002377890, 1002590470, 1002775330, 1002379610

Other Recalls from BioMerieux SA

Recall # Classification Product Date
Z-0084-2022 Class II MYLA Versions: 4.7, 4.7.1, 4.8, 4.8.1 and 4.8.2... Sep 2, 2021
Z-2225-2021 Class II MYLA software. Used to manage microbiology tes... Jun 22, 2021
Z-0218-2019 Class II NucliSENS¿ Magnetic Extraction Reagents Sep 17, 2018
Z-2331-2018 Class II VIDAS FSH, Ref 30407-01, IVD, Rx. The firm nam... Apr 9, 2018
Z-2169-2018 Class II VIDAS TOXO IgG Avidity is an automated qualitat... Mar 23, 2018

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.